What You Should Know:
–Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data, today announced the launch of six new hematology Panoramic datasets, representing another critical moment of scientific innovation that foundationally redefines the company’s real-world evidence offerings in blood cancers.
– Flatiron’s Panoramic data unlocks the company’s entire patient network, leveraging breakthrough AI and large language model capabilities alongside their extensive database to extract and validate clinical data at unprecedented scale.
Flatiron Health expands hematology research capabilities through AI-powered real-world datasets
Flatiron Health, an independent affiliate of the Roche Group, is advancing real-world oncology research with the release of its new hematology Panoramic datasets, encompassing more than 505,000 patient records across five B-cell lymphoma subtypes and multiple myeloma. The datasets are part of a broader repository of over five million cancer patient records, representing 1.5 billion data points that reflect real clinical practice across diverse care settings. Together, they aim to transform how hematologic malignancies are studied, understood, and treated by enabling data-driven insights that mirror patients’ real-world experiences.
Developed under Flatiron’s validated data quality framework, the Panoramic datasets mark a six-fold increase in cohort size compared to the company’s prior hematology collections. They capture extensive longitudinal details including measurable residual disease (MRD) testing and CAR-T therapy utilization—two key indicators of contemporary hematology practice. This depth of clinical information allows researchers to examine modern treatment patterns, adherence, and outcomes with greater precision, supporting the development of personalized therapeutic strategies and more inclusive trial designs.
Chief Executive Officer Nathan Hubbard described the datasets as a culmination of Flatiron’s decade-long effort to build a global oncology evidence infrastructure. He noted that combining the company’s proven AI and machine learning capabilities with scientific rigor enables more precise, individualized care for patients with blood cancers. The new datasets also improve interoperability, allowing streamlined analyses across related lymphoma types and longitudinal tracking of disease transformation over time.
Flatiron’s hematology program supports detailed investigations into complex subgroups such as high-grade B-cell lymphomas with MYC, BCL2, and BCL6 rearrangements or multiple myeloma cases with high-risk cytogenetics. The data also facilitate assessment of real-world effectiveness, molecular response, and adverse events—dimensions that complement evidence from traditional clinical trials. By providing integrated insight into inpatient and outpatient care, infusion and oral regimens, and cellular therapies, the datasets create a panoramic view of the patient journey that was previously fragmented.
With more than 250 publications and 275 upcoming research presentations across global conferences in 2025, Flatiron continues to shape the evidence standards of digital oncology. Its participation at ISPOR Europe and ASH 2025 underscores a broader goal: to responsibly apply artificial intelligence and real-world evidence toward expanding scientific access to rare disease populations, closing persistent data gaps, and accelerating the next generation of hematology innovation.
